The primary aim of the current management of diabetes mellitus is to achieve and/or maintain a glycated hemoglobin level of ≤6.5%. However, recent evidence indicates that intensive treatment of hyperglycemia is characterized by increased weight gain, severe hypoglycemia and higher mortality. Besides, evidence suggests that it is difficult to achieve and/or maintain optimal glycemic control in many diabetic patients; and that the benefits of intensively-treated hyperglycemia are restricted to microvascular complications only. In view of these adverse effects and limitations of intensive treatment of hyperglycemia in preventing diabetic complications, which is linked to oxidative stress, this commentary proposes a hypothesis that "simultaneous targeting of hyperglycemia and oxidative stress" could be more effective than "intensive treatment of hyperglycemia" in the management of diabetes mellitus.
factor of increased ROS production, causes tissue damage or diabetic complications have been identified [14] . These include: hyperglycemia-enhanced polyol pathway; hyperglycemia-enhanced formation of advanced glycation endproducts (AGEs); hyperglycemia-activated protein kinase C (PKC) pathway;
hyperglycemia-enhanced hexosamine pathway; and hyperglycemia-activated Poly-ADP ribose polymerase (PARP) pathway [14] . These pathways are activated or enhanced by hyperglycemia-driven mitochondrial superoxide overproduction [14] .
Even though oxidative stress plays an important role in its pathogenesis and complications, unlike other diseases characterized by oxidative stress, diabetes mellitus is unique. Its cure (restoration of euglycemia, e.g., via pancreas transplants) does not prevent oxidative stress and diabetic complications [16] [17] [18] . This is very important because hyperglycemia exacerbates oxidative stress which is linked to diabetic complications [14, 18] . Theoretically, restoration of euglycemia should prevent oxidative stress and diabetic complications. However, this is not the case [16] [17] [18] . At present, it remains unclear why restoration of euglycemia does not automatically prevent oxidative stress and diabetic complications. Phrases such as "hyperglycemic memory", "glycemic memory", "metabolic memory", or simply "lasting memory" have been introduced to describe this difficult-to-explain observation or phenomenon [14, 18] . The phrase or term refers to the development of diabetes-related complications (both microvascular and macrovascular) in diabetic patients after normoglycemia has been restored [14, 18, 19] . It is a phenomenon whereby previous hyperglycemic milieu is remembered in many target organs such as heart, eyes, kidneys and nerves [14, 18, 19] . This phenomenon is also documented in diabetic animals [16, 17] . Compelling evidence implicates the role of oxidative stress as an important mechanism by which glycemic memory causes tissue damage and diabetic complications [14, 18, 19] .
Considering that intensive therapy of hyperglycemia is associated with increased weight gain, severe hypoglycemia and higher mortality than standard therapy of hyperglycemia [4] [5] [6] 11] , theoretically, discontinuation of intensive therapy should reduce or minimize these adverse effects. However, in view of higher incidence of diabetic complications (of which oxidative stress plays an important role) in conventionally-treated diabetic patients [2, 3] , targeting oxidative stress in these patients might be beneficial. In other words, it is possible that the combination of a conventional therapy of hyperglycemia and antioxidant therapy might be more effective and beneficial than intensive therapy of hyperglycemia alone, which is the gold standard at the moment. Besides, this combination might also be devoid of the intensive therapy-associated adverse effects (increased weight gain, severe hypoglycemia and higher mortality) [4] [5] [6] 11] . At this juncture, the question that arises is: "is there evidence in support of such a hypothesis?" At the moment, there are no findings in large-scale clinical trials that corroborate this hypothesis. However, there are experimental and clinical data, though limited, that suggest simultaneous target of hyperglycemia and oxidative stress might be a better therapeutic option in the management of diabetes mellitus.
A study that targeted hyperglycemia and oxidative stress with insulin and antioxidants (vitamin E and C), respectively in diabetic rats found that the combination of these two classes of agents normalized hyperglycemia, weight loss and oxidative stress parameters more considerably than either agent [20] . Similarly, in diabetic rats, targeting hyperglycemia and oxidative stress with glibenclamide or metformin and antioxidant (honey), respectively improved glycemic control, lipid profile and renal function [21] . Likewise, simultaneous target of hyperglycemia and oxidative stress ameliorated oxidative stress in pancreas [22, 23] and kidney [24] of diabetic rats more considerably than targeting hyperglycemia alone. Additional evidence in support of this hypothesis comes from a study by Qiang and co-workers [25] . The authors found that neither gliclazide (a free radical scavenger) nor glibenclamide had an effect on glycemia in both non-diabetic and diabetic rats [25] . However, the study indicated gliclazide (but not glibenclamide) was beneficial in ameliorating oxidative stress and related parameters [25] . The study also found that gliclazide but not glibenclamide prevented reduced myelinated fiber area, increased fiber density and decreased axon/myelin ratio in diabetic rats [25] . This study clearly shows that targeting oxidative stress, irrespective of the hyperglycemia, prevents peripheral neuropathy in diabetic rats [25] .
In humans with type 1 or type 2 diabetes mellitus, it was reported that maintenance of optimal glycemic control alone was less effective in ameliorating oxidative stress compared to when optimal glycemic control was combined with antioxidant (vitamin E) therapy [26, 27] . A study showed that treatment of type 2 diabetic patients with gliclazide ameliorated oxidative stress compared with baseline and the glibenclamide-treated diabetic patients [28] . Interestingly, the levels of blood glucose and glycosylated hemoglobin were elevated and similar in both groups. It thus indicates that oxidative stress can be controlled irrespective of hyperglycemia [28] . This study suggests that an antioxidant or a free radical scavenger, such as gliclazide, combined with conventional therapy of hyperglycemia could be beneficial in diabetic patients. Another study by Ceriello and colleagues also demonstrated the beneficial effects of targeting hyperglycemia and oxidative stress simultaneously using insulin and antioxidant (vitamin C), respectively on oxidative stress and endothelial dysfunction [29] . The authors reported that neither insulin treatment (despite normalization of hyperglycemia) nor antioxidant therapy (vitamin C) was able to sufficiently ameliorate oxidative stress or normalize endothelial dysfunction [29] . On the contrary, combination of the two agents considerably and adequately ameliorated oxidative stress and normalized endothelial dysfunction in type 1 diabetic patients [29] .
By and large, these studies indicate that co-administration of oral hypoglycemic drugs (and/or insulin) and antioxidants (honey or vitamins C and E) does not reduce or interfere with the hypoglycemic or antioxidant effect of either agent. Therefore, a combination of these two classes of agents is justifiable in the management of diabetes mellitus. With the combination, hypoglycemic drugs will target hyperglycemia to improve glycemic control. In view of evidence which implicates hyperglycemia as the sole contributor of ROS and oxidative stress in diabetes mellitus, targeting hyperglycemia may also be beneficial in reducing oxidative stress [28] . On the other hand, antioxidant therapy will help to ameliorate oxidative stress. Besides, some antioxidants have hypoglycemic effect and improve glycemic control [21, 30, 31] . As demonstrated in some of those studies, antioxidant therapy has a potential to ameliorate oxidative stress in different compartments including the blood vessels and tissues which are targets of oxidative stress and diabetic complications. These include, but are not limited to, retina [16, 17] , pancreas [22, 23] , kidney [24, 30] , nerves [25] , vasculature [29] and erythrocytes [31] . Considering the potential limitations of antioxidant therapy, other therapeutic manipulations of oxidative stress such as mitochondria-targeted antioxidants, inhibition of the mitochondrial ROS overproduction, or inhibition of hyperglycemia-activated pathogenic and signaling pathways are viable complementary options. Any of these could be combined with hypoglycemic agents.
Besides, targeting hyperglycemia and oxidative stress may also offer additional benefits. These include amelioration of oxidative stress and damage in the pancreas [22, 23, 32] . In the case of pancreas, antioxidant therapy may help to reduce glucotoxicity (mediated via oxidative stress), prevent deterioration of beta-cell function and improve glycemic control [33, 34] . Targeting hyperglycemia and oxidative stress may help to ameliorate lipid abnormalities (e.g., elevated low-density lipoproteins (LDLs)) and improve oxidative stress [21, 35] , which increases the susceptibility of LDLs to oxidation and glycation. This may prevent atherosclerosis and endothelial dysfunction. Antioxidants have further been shown to improve insulin resistance, insulin levels and C-peptide in diabetic rats [21, 36, 37] . Targeting hyperglycemia and oxidative stress may help to ameliorate intestinal oxidative stress and increase the bioavailability of essential macronutrients or co-administered antidiabetic agents [38, 39] . Furthermore, antioxidants may help to ameliorate liver damage and hepatic oxidative stress which are common in diabetes mellitus [40, 41] . Considering the roles of the liver in glucose homeostasis and in mediating the hypoglycemic effect of antidiabetic agents such as glibenclamide, antioxidant therapy may improve liver function and contribute to improved glycemic control. Moreover, co-administration of hypoglycemic drugs with antioxidants may help to prevent weight gain commonly observed with hypoglycemic drugs, especially glibenclamide [42] . This may be advantageous in obese or overweight type 2 diabetic patients. Moreover, since many diabetic patients usually develop hypertension which is also associated with oxidative stress, antioxidants may help to prevent or delay the development of hypertension and diabetic complications [43, 44] . In addition, targeting hyperglycemia and oxidative stress concurrently may require lower doses of antidiabetic drugs, which in turn may help to minimize the adverse effects or toxicities of these agents.
In a nutshell, in view of the compelling evidence that demonstrates an association between an intensive therapy of hyperglycemia, it would be worthwhile to reconsider any therapeutic goal that target "hyperglycemia or glycemic control alone" in diabetic patients. Instead, targeting hyperglycemia and oxidative stress simultaneously might be a better option. While this commentary does not underestimate the importance of optimal glycemic control, however, the data, views and explanations presented or posited, do strengthen the hypothesis that the prospect of managing diabetes mellitus more effectively by targeting hyperglycemia and oxidative stress concurrently holds much promise. This hypothesis is worth investigating in diabetic patients. Therefore, both small and large randomized clinical trials that investigate the effects of targeting hyperglycemia and oxidative stress simultaneously in patients with type 1 or type 2 diabetes mellitus are highly desirable. Also, clinical trials that compare the effects of a standard or conventional therapy of hyperglycemia and antioxidant therapy with those of intensive therapy of hyperglycemia alone are also recommended. These clinical trials would help to substantiate or perhaps refute this hypothesis in diabetic human subjects.
